Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center
Vyriad, Inc.
TCR2 Therapeutics
Yale University
Bristol-Myers Squibb
Duke University
University of Utah
Fundación GECP
Agenus Inc.
Oslo University Hospital